PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: IMARC Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biotech Growth to Slow Down in the U.S in the Coming Years Reports IMARC Group - Recombinant proteins, which currently account for around 60% of the total US biopharmaceutical sales, are expected to be the worst hit during the forecast period - IMARCgroup.com
Biotech Growth to Slow Down in the U.S in the Coming Years Reports IMARC Group

 

NewswireToday - /newswire/ - Ghaziabad, Uttar Pradesh, India, 2013/03/19 - Recombinant proteins, which currently account for around 60% of the total US biopharmaceutical sales, are expected to be the worst hit during the forecast period - IMARCgroup.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A new report from IMARC Group expects the biopharmaceutical market in the US to grow at a CAGR of around 5% during 2012-2017. This is significantly lower than the average 8-9% growth rate observed in this market in the last five years.

According to an analyst at IMARC Group,“the rise of biosimilars in the US is expected to have a major impact on market growth. Recombinant proteins, which currently account for around 60% of the total US biopharmaceutical sales, are expected to be the worst hit during the forecast period. During 2012-2017, we expect nine biological brands in this segment to face biosimilar competition. Recombinant proteins are expected to witness a CAGR growth of less than 3% during this period. The growth of monoclonal antibodies, on the other hand, is expected to be significantly faster than recombinant proteins during the forecast period. The key factors driving the monoclonal antibodies will be a rich pipeline and approval of additional indications for currently marketed drugs. Although some monoclonal antibodies such as Rituxan and Humira may face biosimilar competition, we expect significantly lower biosimilar threat for monoclonal antibodies during the forecast period compared to recombinant proteins.

IMARC’s new report “Global Biopharmaceutical Market Report & Forecast (2012-2017)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2017. This report will serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in any form.

What We Have Achieved in this Report?

Deep Qualitative Understanding of Various Factors Driving and Restraining the Global Biopharmaceutical Market
Key Aspects Analyzed:
• Driving Factors
• Restraining Factors
• Market Opportunities
• Threats

Comprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics
Regions/Countries Covered:
North America: United States and Canada
Latin America: Mexico, Brazil and Argentina
Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey
Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia

Classes Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones, Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes, Growth Factors, Interleukins, Monoclonal Antibodies and Purified Proteins

Focus of the Analysis for Each Country:
• Total Market Performance (2005 - 2011)
• Performance of Various Classes (2005 - 2011)
• Performance of Top Players (2005 - 2011)
• Market Forecast (2012 - 2017)

Key Questions Answered in this Report:
• What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.?
• What are the key opportunities and threats faced by the biopharmaceutical industry?
• What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years?
• Which are the world’s largest biopharmaceutical markets?
• Which are the world’s fastest growing biopharmaceutical markets?
• What is the structure and composition of various biopharmaceutical markets across the globe?
• Which are the world’s largest biopharmaceutical segments?
• Which are the world’s fastest growing biopharmaceutical segments?
• Who are the world’s largest biopharmaceutical companies and how have they performed in recent years?

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Biotech Growth to Slow Down in the U.S in the Coming Years Reports IMARC Group

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com / america[.]imarcgroup.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IMARC Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Rapid Recovery

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)